Reference Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Ref Type

PMID

Authors

Drew W. Rasco, Ryan J. Sullivan, Nehal J. Lakhani, Sanjeeva Reddy, Niranjan Sathyanarayana Rao, Louis J. Denis, Anthony W. Tolcher, Keith Flaherty

Title

ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors

Journal	Vol	Issue	Date	Pages	Journal Short Title
Journal of Clinical Oncology

URL

Abstract Text

J Clin Oncol 35, 2017 (suppl; abstr e14102)

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
ASN003	ASN003	4	1

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
ASN003		ASN-003\|ASN 003	BRAF Inhibitor 26 PIK3CA inhibitor 26 PIK3CG inhibitor 10	ASN003 is a small molecule inhibitor of BRAF, PIK3CA, and PIK3CG, which may result in inhibition of cell proliferation and antitumor activity (J Clin Oncol 35, 2017 (suppl; abstr e14102)).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF V600X	melanoma	sensitive	ASN003	Preclinical - Pdx	Actionable	In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).	detail...